🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Only 1️⃣0️⃣ days until #TCT2024! Join us in Washington, DC to hear expert faculty discuss how the #FFRangio System has redefined what a physiology solution can deliver in daily practice. Chair: Dr. Martin B. Leon Presenters: Dr. William F. Fearon , Prof. Hitoshi Matsuo, and Dr.

The countdown is nearly over - #TCT2024 starts on Sunday! Join us in Washington, DC for a packed meeting, including a lunch symposium with expert faculty and scientific presentations featuring the #FFRangio System throughout the conference. Don’t miss your opportunity to

Read how the CathWorks #FFRangio System is enhancing the way doctors at AdventHealth detect and treat coronary artery disease, making procedures safer and less burdensome for patients. Dr. Dean Abtahi highlights, “This is about making sure we are treating patients in the safest

CathWorks announces key events for the annual TCT conference kicking off this weekend in Washington, DC. The CathWorks #FFRangio® System will be featured in multiple scientific presentations including the first ever prospective RCT comparing an angio-based physiology tool versus

Today at the #TCT2024 conference, Professor Hitoshi Matsuo from Gifu Heart Center shared results from the PROVISION Study, the first RCT of FFRangio outcomes compared to invasive wire-based FFR. The study met its primary endpoint and revealed significant economic and resource

#PROVISION trial—> prospective randomized trial comparing clinical outcomes of angio based FFR with wire based FFR—> shows similar revascularization rates with the two techniques. Clinical outcomes will be assessed at 1 yr follow up! #TCT2024 Cardiovascular Research Foundation #ACCIC #FFR MIЯVΛƬ #IC

Congratulations to Prof. Hitoshi Matsuo for his presentation on the PROVISION Study today at #TCT2024, where the theatre was standing room only. Prof. Matsuo showed that the study met its primary endpoint and revealed significant economic and resource utilization advantages for

My #TCT2024 highlight today was the excellent session on coronary physiology: FFRangio in PROVISION, PPG, and iFR/FFR in ORBITA-2 TCT Conference Center for Coronary Artery Disease Pedro E.P. Carvalho, MD

Congratulations to Dr. Allen Jeremias, Dr. Ajay Kirtane, Prof. Hitoshi Matsuo, and Dr. William Fearon for a fantastic #TCT2024 lunchtime symposium that was standing room only! The audience was eager to learn about how the CathWorks #FFRangio System is bringing the benefits of

🎥Behind the scenes at #TCT2024! Stay tuned for the latest CathWorks insights and updates. #TheNewEraInPhysiology

Congratulations to Dr. Kazuhiro Dan for presenting his latest data comparing #FFRangio and IVUS measurements, showing excellent correlation between the two modalities with regards to lesion length and vessel diameters. We’re grateful to Dr. Dan for his ongoing contribution to

FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in The Lancet. thelancet.com/journals/lance… #CardioX #CardioTwitter #CardioEd #CardioResearch

#TheNewEraInPhysiology is here. Don’t just take our word for it. Hear from the experts. #TCT2024 | Morton J Kern | Ankitkumar Patel MD MPH FACC FSCAI RPVI | Shailendra Singh

Humbled and honored to be able to share my passion for coronary physiology along with the luminaries, Morton J Kern! Excited about having this innovative and disruptive technology at Mountainside Medical Center! We are truly delivering tomorrow’s care - today. Ramin Mousavi CathWorks

Mamas A. Mamas giving editorial review of LBCT FAVOR III trial TCT Conference ➡️QFR inferior to FFR #TCT24 Cardiovascular Research Foundation David L. Fischman jedicath աǟզǟʀ.ǟɦʍɛɖ Sarah Fairley Poonam Velagapudi David J. Cohen, MD, MSc Ki Park Luis Ortega Paz

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe dlvr.it/TFv3Sz

Congratulations to Prof. Guy Witberg for presenting his latest real-world #FFRangio outcomes data at #TCT2024. In a real-world setting, FFRangio-guided treatment demonstrated excellent 2-year outcomes for both ACS and CCS patients, which are comparable with current data for

It’s Friday! 🎉

🫀 The world of coronary physiology is transforming, and #TCT2024 showcased just how far we’ve come! It’s clear— #TheNewEraInPhysiology is here, and it’s powered by the #FFRangio System.

Mamas Mamas (Mamas A. Mamas), BMBCh, DPhil, gives his view on the FAVOR III Europe trial, which assessed QFR versus FFR for coronary revascularisation guidance, presented at #TCT2024. TCTMD